Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (Nasdaq:ASLN), an immunology-focused biopharmaceutical company, announced that CEO Dr. Carl Firth will present at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The virtual presentation will be accessible on demand starting January 10, 2022, at 07:00 AM ET through ASLAN's Investor Relations website. ASLAN is developing innovative treatments, including ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases, highlighting its commitment to transforming patient lives.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has appointed IQVIA Biotech as its preferred clinical research organization for decentralized trials concerning ASLAN004 and ASLAN003. This partnership will enhance logistical support, patient recruitment, and clinical monitoring for the upcoming Phase 2b trial of ASLAN004 targeting moderate-to-severe atopic dermatitis. Enrollment for this trial is expected to begin in Q4 2021. The collaboration aims to leverage IQVIA's expertise, aiming to streamline patient engagement across multiple regions, including the US, Canada, Europe, and Asia.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced participation by CEO Dr. Carl Firth in two virtual health conferences. The first, the Piper Sandler 33rd Annual Virtual Healthcare Conference, will feature a recorded discussion available on November 22, 2021, at 10:00 am ET. The second event is the 4th Annual Evercore ISI HealthCONx Conference, scheduled for December 2, 2021, at 8:50 am ET, located in Track 3. Both discussions can be accessed later on ASLAN's Investor Relations website.
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will attend the 12th Annual Jefferies London Healthcare Conference in-person on November 17, 2021, at 1:00 PM GMT. The conference runs from November 16-17, 2021, in-person, and virtually from November 18-19, 2021. A live webcast of the discussion will be available, with a replay accessible on ASLAN’s Investor Relations website. ASLAN is focused on developing innovative treatments for immunology and is evaluating ASLAN004 and ASLAN003 for various conditions.
ASLAN Pharmaceuticals (Nasdaq: ASLN) reported positive results from its Phase 1 trial of ASLAN004 for atopic dermatitis, achieving significant improvements in primary and secondary endpoints. The company plans to initiate a Phase 2b trial with 300 patients in Q4 2021. Financially, ASLAN's Q3 2021 cash usage was $7.6 million, with a net loss of $8.6 million, up from $3.5 million in Q3 2020. The cash balance stood at $100.5 million, projected to fund operations into late 2023.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced a collaboration with Dr. Emma Guttman-Yassky to enhance research on ASLAN004 in treating moderate-to-severe atopic dermatitis (AD). Dr. Guttman-Yassky will evaluate biomarkers linked to inflammation in AD, aiming to uncover the treatment mechanisms of ASLAN004. Previous Phase 1b trial results indicated that ASLAN004 successfully met primary and secondary endpoints, showcasing its potential as a novel therapy for AD. The company expects to enroll the first patient in its Phase 2b study within the fourth quarter of 2021.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announces the first in a series of Key Opinion Leader (KOL) webinars on the atopic dermatitis treatment landscape, starting October 25, 2021. The company is on track to enroll the first patient in its global, 300-patient Phase 2b study of ASLAN004, a potential first-in-class monoclonal antibody targeting the IL-13 receptor. Results from a recent Phase 1b MAD trial showed ASLAN004 achieved significant improvements over placebo in primary efficacy endpoints, establishing proof of concept and demonstrating well-tolerated safety across doses.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced new appointments to its Scientific Advisory Board (SAB), including Dr. Melinda Gooderham, Dr. Jacob Thyssen, and Associate Professor Peter Foley. This move aims to enhance ASLAN's clinical development pipeline in immunology, particularly targeting atopic dermatitis through the lead asset ASLAN004. The SAB, chaired by Dr. Lawrence Eichenfield, is assembled to leverage global expertise in allergic and inflammatory diseases, supporting the initiation of a phase 2b study later this quarter.
ASLAN Pharmaceuticals announced positive topline data from a Phase 1 study of ASLAN004, a monoclonal antibody targeting IL-13 receptor for treating moderate-to-severe atopic dermatitis. The study demonstrated a statistically significant improvement in Eczema Area Severity Index (EASI) by 65% compared to placebo (27%). Other efficacy endpoints also showed significant benefits. ASLAN004 was well-tolerated with no reported cases of conjunctivitis. The company plans to enroll the first patient in a global Phase 2b study in Q4 2021.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that Dr. Carl Firth, CEO, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20 AM ET. The conference takes place from September 27 to September 30, 2021. A live webcast of the presentation will be available on ASLAN's Investor Relations website and will be archived for 365 days. ASLAN is focused on developing innovative treatments in immunology, including its candidates ASLAN004 and ASLAN003 for atopic dermatitis and autoimmune diseases, respectively.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
